Status:

COMPLETED

Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma

Lead Sponsor:

Oslo University Hospital

Conditions:

Malignant Melanoma

Eligibility:

All Genders

18-75 years

Phase:

PHASE1

PHASE2

Brief Summary

Primary objective: Determination of safety and tolerability of GV1001 administration combined with Temozolomide (based on blood samples and adverse events). Feasibility of combining active immunisati...

Eligibility Criteria

Inclusion

  • Histologically confirmed diagnosis of malignant melanoma.
  • Previously untreated and non-resectable disease
  • Measurable or evaluable tumour.
  • Age ≥ 18 and ≤ 75 years.
  • Performance status ECOG-WHO 0, 1 and 2 (Appendix III)
  • Written informed consent (Appendix II)
  • Adequate bone marrow liver, heart and renal function:
  • WBC count \>3.0 x 109/L and platelets count \>100 x 109/L.
  • ASAT, ALAT \<2 x upper normal laboratory value.
  • Serum creatinine \<2 x upper normal laboratory value.

Exclusion

  • Previous treatment with chemotherapy.
  • Clinical signs of brain metastases.
  • Severe cardiac insufficiency (NYHA III or IV) with uncontrolled and/or unstable cardiac or coronary artery disease.
  • Severe active infections such as HIV or hepatitis B or Hepatitis C.
  • Medication for severe intercurrent disease which might affect immunocompetence (e.g. immunosuppressants, systemic corticosteroids).
  • Pregnancy, breast-feeding or absence of adequate contraception for fertile patients.
  • Simultaneously participation in other clinical studies.
  • Any reason why, in the opinion of the investigator, the patient should not participate.

Key Trial Info

Start Date :

January 1 2005

Trial Type :

INTERVENTIONAL

End Date :

September 1 2012

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT01247623

Start Date

January 1 2005

End Date

September 1 2012

Last Update

November 5 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Oslo University Hospital

Oslo, Postbox 4953, Norway, 0424